It also covered risk-reducing mastectomy (RRM), risk-reducing salpingo-oophorectomy (RRSO), reconstructive surgery, and surveillance for breast or ovarian cancer patients carrying a BRCA1/2 pathogenic or likely pathogenic mutation. This evidence concerns the gene BRCA1 and ovarian cancer.